Targeting adipokines: A new strategy for the treatment of myocardial fibrosis

Area of Science:

• Cardiovascular Research
• Metabolic Signaling
• Fibrosis Pathogenesis

Background:

• Cardiac fibrosis is a major contributor to cardiovascular diseases (CVD), impacting health and economy.
• Adipokines, secreted by adipose tissue, regulate metabolism, inflammation, and cardiovascular function.
• Understanding adipokine roles is crucial for developing effective myocardial fibrosis treatments.

Purpose of the Study:

• To review the role of adipokines in regulating cardiac fibrosis.
• To explore adipokines as potential therapeutic targets for myocardial fibrosis.
• To propose strategies for developing novel pharmacological treatments based on adipokine activity.

Main Methods:

• Literature review of scientific studies on adipokines and cardiac fibrosis.
• Analysis of adipokine functions in relation to myocardial fibrosis progression.
• Synthesis of current evidence on adipokine-targeted therapies.

Main Results:

• Adipokines, including adiponectin, leptin, resistin, visfatin, and omentin, are implicated in cardiac fibrosis.
• Evidence suggests adipokines can modulate the development and progression of myocardial fibrosis.
• Targeting specific adipokines presents a promising avenue for novel therapeutic interventions.

Conclusions:

• Adipokines represent a significant therapeutic target for managing cardiac fibrosis.
• Further research into adipokine activity can lead to the development of safe and effective pharmacological agents.
• Targeting adipokines offers a new strategy for treating myocardial fibrosis and related cardiovascular diseases.